Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
(SIMPLICITY Trial)
Recruiting in Palo Alto (17 mi)
+211 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: Bristol-Myers Squibb
No Placebo Group
Trial Summary
What is the purpose of this trial?
The purpose of this study is to better understand the use of tyrosine kinase inhibitors (TKI) in patients newly diagnosed with CML and their quality of life in a real-world setting.
Research Team
BS
Bristol-Myers Squibb
Principal Investigator
Bristol-Myers Squibb
Eligibility Criteria
Inclusion Criteria
Newly-diagnosed chronic phase chronic myeloid leukemia (CP-CML) patients who started their first-line Tyrosine Kinase Inhibitor (TKI) treatment on imatinib, dasatinib or nilotinib in accordance with the timelines below
a) Imatinib Cohorts
Patients who started their first-line Dasatinib treatment after the drug was approved in this indication
See 7 more
Treatment Details
Interventions
- Non-Interventional (Other)
Participant Groups
4Treatment groups
Experimental Treatment
Group I: Imatinib treated patientsExperimental Treatment1 Intervention
Imatinib treated patients if their study index date is between January 2, 2008 and September 30, 2010
Group II: First line TKI treatment: NilotinibExperimental Treatment1 Intervention
Diagnosed CML patients who receive first line TKI treatment: Nilotinib
Group III: First line TKI treatment: ImatinibExperimental Treatment1 Intervention
Diagnosed CML patients who receive first line TKI treatment: Imatinib
Group IV: First line TKI treatment: DasatinibExperimental Treatment1 Intervention
Diagnosed CML patients who receive first line TKI treatment: Dasatinib
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Central DuPage HospitalWinfield, IL
MD Anderson Cancer CenterHouston, TX
City Hospital - West Virginia University Hospital EastMartinsburg, WV
Aspirus Regional Cancer CenterWausau, WI
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
Bristol-Myers Squibb
Lead Sponsor
Trials
2731
Patients Recruited
4,127,000+
Headquarters
New York City, USA
Known For
Oncology & Cardiovascular
Top Products
Eliquis, Opdivo, Revlimid, Orencia
ICON Clinical Research
Industry Sponsor
Trials
52
Patients Recruited
15,100+